Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhongyuan Union Cell & Gene Engineering's quarterly market cap
increased
from Sep. 2025 (¥11,568 Mil) to Dec. 2025 (¥11,792 Mil) and
increased
from Dec. 2025 (¥11,792 Mil) to Mar. 2026 (¥14,460 Mil).
Zhongyuan Union Cell & Gene Engineering's annual market cap
declined
from Dec. 2023 (¥9,485 Mil) to Dec. 2024 (¥9,031 Mil) but then
increased
from Dec. 2024 (¥9,031 Mil) to Dec. 2025 (¥11,792 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Zhongyuan Union Cell & Gene Engineering's Enterprise Value for Today is ¥6,778 Mil.
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Zhongyuan Union Cell & Gene Engineering Market Cap Related Terms
Zhongyuan Union Cell & Gene Engineering Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering Market Cap Chart
Zhongyuan Union Cell & Gene Engineering Annual Data
SHSE:600645 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhongyuan Union Cell & Gene Engineering Market Cap vs Biotechnology Industry
Zhongyuan Union Cell & Gene Engineering Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) has a Market Cap of ¥8,465 Mil as of Jul. 16, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. According to the industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #247 out of 1423 companies in the Biotechnology industry, placing it in the top 17.4%.
Is Zhongyuan Union Cell & Gene Engineering's Market Cap too high?
Zhongyuan Union Cell & Gene Engineering's current Market Cap is ¥8,465 Mil. Based on the distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #247 out of 1423 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zhongyuan Union Cell & Gene Engineering has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhongyuan Union Cell & Gene Engineering's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #247 out of 1423 companies for Market Cap. This places Zhongyuan Union Cell & Gene Engineering in the top 17% of its industry — outperforming the majority of peers. The industry median Market Cap is 117.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.38, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. For the Biotechnology industry, the median Market Cap is 117.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhongyuan Union Cell & Gene Engineering's current Market Cap is ¥8,465 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongyuan Union Cell & Gene Engineering stock overvalued right now?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering (SHSE:600645) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥20.36, compared to a current price of ¥18.09 — trading 11.1% below its estimated fair value. The current Market Cap is ¥8,465 Mil. Zhongyuan Union Cell & Gene Engineering's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Zhongyuan Union Cell & Gene Engineering (SHSE:600645), the current Market Cap is ¥8,465 Mil as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Overvalued in 2026?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering stock appears to be undervalued.
The current stock price of ¥18.09 is trading 11.1% below its estimated GF Value™ of ¥20.36.
GuruFocus considers Zhongyuan Union Cell & Gene Engineering to be Modestly Undervalued.
Key valuation signals for SHSE:600645:
Market Cap: ¥8,465 Mil
GF Value™: ¥20.36 vs. price of ¥18.09 (11.1% below fair value)
No single metric tells the full story. See the SHSE:600645 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhongyuan Union Cell & Gene Engineering Business Description
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
60GF Score
Get the complete analysis for SHSE:600645
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600645 has been successfully added to your 
